"The combination of VS-6063 and paclitaxel was well tolerated at all doses with no exacerbation of the well-known adverse effects of paclitaxel" Members of the Verastem leadership team provided an overview of the Company's development programs targeting cancer stem cells through the inhibition of focal adhesion kinase and PI3K/mTOR signaling ... (more)
http://www.businesswire.com/news/home/20130711006401/en/Verastem-Presents-Results-Updated-Development-Plans-Annual
http://www.businesswire.com/news/home/20130711006401/en/Verastem-Presents-Results-Updated-Development-Plans-Annual
No comments:
Post a Comment